However, NAD+ therapy is not for everyone
KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)
Type 2 diabetes Type 2 diabetes affects more than 800 million people worldwide, and individuals with diabetes are about twice as likely to experience depression as the general population
Even at a low dose, many patients notice reduced appetite, steadier energy, and more natural portion sizes
Seek same-day medical advice or attend A&E if you develop: Severe hypoglycaemia requiring assistance from another person, loss of consciousness, or seizures Diabetic ketoacidosis symptoms : excessive thirst, frequent urination, fruity-smelling breath, confusion, or rapid breathing (though less common in type 2 diabetes, it can occur) Severe abdominal pain that is persistent and may indicate pancreatitis or gallbladder disease Signs of severe dehydration : dizziness, reduced urine output, confusion, or rapid heartbeat Allergic reactions : difficulty breathing, facial swelling, or widespread rash Routine situations that warrant scheduled contact include: Planning pregnancy or discovering you are pregnant, as both medications require specialist review and potential adjustment Scheduling surgery or procedures requiring fasting, as medication timing and doses need modification Starting new medications that may interact with glucose control (such as corticosteroids, certain antibiotics, or other diabetes medications) Experiencing persistent gastrointestinal side effects that affect your quality of life or ability to maintain adequate nutrition Noticing unexplained weight loss beyond expected effects, persistent fatigue, or other concerning symptoms DVLA and driving advice: If you are taking insulin, you must inform the DVLA
